Life Sciences: Supply Chain Resilience Amid Geopolitical and Capacity Volatility

Why This Matters Now

Life sciences procurement is operating in a structurally fragile environment. Geopolitical tensions, trade policy shifts, and deep geographic concentration have outpaced traditional riskmodels.

By 2026, below realities dominate:

~80% of global  generic API supply chain controlled by China

~70% of India's API  intermediates sourced from China

11% Biologics  CDMO* market CAGR (2025-2032)

~41% of  FDA-registered API sites are in China or India

Sources: LGM Pharma (March 2025); PharmaSource / P&S Intelligence (2024); DrugPatentWatch (2025)

*CDMO – Contract Development and Manufacturing Organisations)
‍

Switching from a Chinese API to an Indian formulator often means relying on the same upstream ecosystem. This is concentration by proxy, not diversification.

‍

How Supply Chain Risk Is Being Redefined

Regulatory and Trade Policy Risk

Legislation such as the BioSecure Act could restrict federal contracts with firms linked to certain foreign supply chains, affecting China-exposed CDMOs. Section 232 reviews on pharmaceutical imports reflect rising national security scrutiny in U.S. trade policy. Targeted tariffs remain a plausible outcome.

Despite tariffs on Chinese pharmaceutical chemicals since 2018, China’s share of U.S. Food and Drug Administration-registered API sites has continued to grow. Regulatory risk is now structural, not cyclical.
‍

Biologics Capacity Constraints

Large-scale bioreactor capacity is tightly held, with multi-year expansion timelines:

• Samsung Biologics reported near-full utilization across ~362,000L capacity in 2024.
• Lonza acquired Roche’s Vacaville site for USD 1.2B and is investing CHF 500M in expansion.
• The biologics CDMO market is projected to grow from USD 17.1B (2024) to USD 39B by 2032 (~11% CAGR).

Organizations without capacity reservations or dual CDMO qualifications risk being priced out during the next demand surge.

‍

Strategic Imperatives for 2026

• Map true exposure beyond tier
  Trace API origin for critical materials. Identify sub-tier country exposure and pre-qualify at least one geographically independent alternate per category.
  ‍
• Make dual sourcing operational
  Allocate 10–20% volume to secondary suppliers. Dormant alternates do not reduce risk.
  ‍
• Monitor risk continuously
  Integrate financial health indicators, compliance alerts from the European Medicines Agency and U.S. Food and Drug Administration, and trade-policy updates into live dashboards.
  ‍
• Govern supply risk like performance
  Track KPIs: single-source exposure (<15% tier-1 critical), disruption detection(<48 hours), and alternate readiness (% active within 12 months).

‍

The Bottom Line

Risk elimination is unrealistic. The objective is to detect faster, pre-planned responses, and lower disruption cost in a volatile environment.

Life sciences procurement must shift from cost-led sourcing to risk-indexed portfolio management - integrating supplier intelligence, geographic diversification, capacity buffers, and continuous monitoring into one operating model.

Organizations that build this capability in 2026 will create structural competitive advantage. Those that do not absorb the full impact of the next geopolitical or capacity shock.

‍

To know more, reach out to us today and take our 5-minute AI Readiness Assessment to evaluate where your organization stands before deploying Agentic AI.

‍

Authored by:
Aditya More
Director - Valorant

‍

‍